AlphaFold previously predicted single conformations with 92% accuracy but missed key structural variants.
The new method integrates NMR spectroscopy data—magnetic resonance measurements of atomic behavior—to guide predictions.
ISTA's team validated their approach on 15 proteins, including the cancer-linked protein KRAS.
Dynamic protein modeling could slash drug trial failures by identifying more precise molecular targets.
The enhanced AlphaFold predicted 3 distinct conformations for KRAS—one matching a previously unknown structure confirmed by NMR.